TestCloud
Prep • Practice • Perform
Log In

India launches first indigenous CRISPR gene therapy "BIRSA 101" for Sickle Cell Disease.

Science & Tech | Dated: 25 Nov 2025

India has achieved a major medical milestone by launching its first indigenous CRISPR-based gene therapy named "BIRSA 101" for the treatment of Sickle Cell Disease. Developed by Indian researchers, this therapy aims to provide an affordable cure for the genetic disorder, which affects a large tribal population in India.

🎯 Key Highlights:

  • "BIRSA 101" is India's first fully indigenous gene therapy for Sickle Cell Disease, marking a breakthrough in affordable healthcare for complex genetic conditions.
  • The therapy utilizes the advanced CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology to edit genes and correct the mutation responsible for the disease.
  • This development is crucial for India's "National Sickle Cell Anaemia Elimination Mission," which aims to eliminate the disease as a public health problem by the year 2047.

💡 Other Important Facts:

  • BIRSA 101 is India's first indigenous gene therapy for Sickle Cell Disease.
  • It utilizes advanced CRISPR technology for gene editing.
  • The therapy addresses the needs of India's tribal population affected by the disease.

📚 Test Your Knowledge:

What is the name of India's first indigenous CRISPR therapy for Sickle Cell Disease?

Correct Answer: BIRSA 101

🚀 Quick Recap:

About Sickle Cell Mission

  • Elimination Target Year – 2047
  • Focus Area – Tribal Populations